Lipotriches exagens

Exagen Inc. Reports Strong Third Quarter 2023 Results

Retrieved on: 
Monday, November 13, 2023
Johns Hopkins University, Webcast, EBITDA, Interest, SAN, LLP, Bank statement, BDO, Net, Depreciation, ASP, XGN, GAAP, Lupus nephritis, Growth, Medicare, Biomarker, CTD, Coal, Bookkeeping, Video game, Bank, Lipotriches exagens

SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023.

Key Points: 
  • SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023.
  • Revenue was $13.4 million for the third quarter of 2023, compared with $14.7 million in the third quarter of 2022 and $14.1 million in the second quarter of 2023.
  • Gross margin was 57.4% in the third quarter of 2023, compared to 58.7% in the second quarter of 2023 and 59.2% in the third quarter of 2022.
  • A conference call to review third quarter 2023 financial results and to provide a business update is scheduled for today, November 13, 2023, at 4:30 PM Eastern Time (1:30 PM Pacific Time).

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

Retrieved on: 
Thursday, November 9, 2023
Johns Hopkins University, Nephritis, Biomarker, Lipotriches exagens, Patient, SAN, Lupus nephritis, MPH, Pharmaceutical industry, MD

SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execution of an exclusive license agreement.

Key Points: 
  • SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execution of an exclusive license agreement.
  • Exagen will focus on the development of novel patented biomarkers for therapeutic management of patients with lupus nephritis.
  • Exagen intends to develop the novel biomarkers into assays to aid diagnostic and treatment decisions by providing unique clinical insight into a specific patient’s lupus nephritis in a non-invasive manner.
  • “We are very excited to accelerate the development of these highly innovative biomarkers for lupus nephritis patient management.

Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023

Retrieved on: 
Monday, October 30, 2023
Interest, Lipotriches exagens, Webcast, SAN, Cryptocurrency

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2023, after the market close on Monday, November 13, 2023.

Key Points: 
  • SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2023, after the market close on Monday, November 13, 2023.
  • John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT).
  • A replay of the conference call will be available until Monday, November 27, 2023, at 11:59 PM ET (8:59 PM PT).
  • Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.

Exagen Inc. Reports Strong Second Quarter 2023 Results

Retrieved on: 
Monday, August 7, 2023
Interest, Webcast, Medicare, ASP, CTD, XGN, Rheumatology, SAN, Video game, Cryptocurrency, Lipotriches exagens

Delivered a record 37,749 AVISE® CTD tests in the second quarter, an 8% increase over the second quarter of 2022.

Key Points: 
  • Delivered a record 37,749 AVISE® CTD tests in the second quarter, an 8% increase over the second quarter of 2022.
  • Recognized total revenue of $14.1 million for the second quarter, a 26% increase over the first quarter of 2023.
  • Gross margin was 58.7% in the second quarter of 2023, compared to 47.2% in the first quarter of 2023 and 20.1% in the second quarter of 2022, primarily due to increased accrual rates due to improved collections from prior periods.
  • For the second quarter of 2023, net loss was $5.0 million, compared to a net loss of $7.7 million in the first quarter of 2023 and a net loss of $14.7 million in the second quarter of 2022.

Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023

Retrieved on: 
Tuesday, July 25, 2023
Interest, Webcast, SAN, Lipotriches exagens, Cryptocurrency

SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, before the market open on Monday, August 7, 2023.

Key Points: 
  • SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2023, before the market open on Monday, August 7, 2023.
  • John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 8:30 AM ET (5:30 AM PT).
  • A replay of the conference call will be available until Monday, August 21, 2023, at 11:59 PM ET (8:59 PM PT).
  • Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.

Exagen Inc. Appoints Paul Kim to Board of Directors

Retrieved on: 
Monday, July 24, 2023
Learning, University, COVID-19, XGN, Certified Public Accountant, Accounting, Genetics, SAN, Autoimmune disease, Berkeley, Growth, Management, Lipotriches exagens

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023.

Key Points: 
  • SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023.
  • Mr. Kim currently serves as Chief Financial Officer of Fulgent Genetics (Nasdaq: FLGT), a full-service genomic testing company built around a foundational technology platform.
  • “We are thrilled to welcome Paul to our Board of Directors at Exagen.
  • “I look forward to learning from his 30 plus years of leadership in business.”
    “I am delighted to join the Board of Directors at Exagen,” said Paul Kim.

Exagen Inc. Reports First Quarter 2023 Results

Retrieved on: 
Monday, May 15, 2023
Interest, Webcast, ASP, CTD, COGS, Absorption, SAN, Video game, Pharmaceutical industry, Lipotriches exagens

SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN)("Exagen"), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN)("Exagen"), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2023.
  • Recognized total revenue of $11.2 million for the first quarter, an 8% increase over the first quarter of 2022.
  • Total operating expenses of $18.9 million for the quarter, a decrease of 5.7% over the first quarter of 2022.
  • A conference call to review first quarter 2023 financial results and to provide a business update is scheduled for today May 15, 2023 at 4:30 PM Eastern Time (1:30 PM Pacific Time).

Exagen Announces Campaign for Lupus Awareness Month

Retrieved on: 
Monday, May 1, 2023
Learning, Partnership, Lupus, Rheumatology, SLE, Patient, SAN, Diagnosis, Health, Lupus Foundation of America, Disease, Pharmaceutical industry, Birth control, Medical device, Lipotriches exagens

SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign focusing on providers, patients and partnership activities that enhance the impactful work being done to help those suffering from Systemic Lupus Erythematosus (SLE).

Key Points: 
  • SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a campaign focusing on providers, patients and partnership activities that enhance the impactful work being done to help those suffering from Systemic Lupus Erythematosus (SLE).
  • Lupus Awareness Month occurs every May and is an opportunity for lupus-focused organizations to take intentional steps in creating awareness around lupus and those impacted.
  • Lupus is a disease that AVISE® testing is specially equipped to help with and today marks the start of a month-long campaign around Bringing Awareness to Lupus Symptoms.
  • Spreading awareness is key and we are proud to work with our partners to cultivate that awareness,” said John Aballi, President and CEO of Exagen.

Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023

Retrieved on: 
Monday, April 24, 2023
Interest, Webcast, SAN, Lipotriches exagens, Cryptocurrency

SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2023, after the market close on Monday, May 15, 2023.

Key Points: 
  • SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2023, after the market close on Monday, May 15, 2023.
  • John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT).
  • A replay of the conference call will be available until Monday, May 29, 2023, at 11:59 PM ET (8:59 PM PT).
  • Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Monday, March 20, 2023
ASP, COGS, Marketing, CTD, Rheumatology, Interest, Medicare, GM, SAN, Webcast, Video game, Cryptocurrency, Pharmaceutical industry, Lipotriches exagens

Record 135,210 flagship AVISE® CTD tests, for the full year 2022, including 33,819 tests for the fourth quarter of 2022.

Key Points: 
  • Record 135,210 flagship AVISE® CTD tests, for the full year 2022, including 33,819 tests for the fourth quarter of 2022.
  • Total revenue of $45.6 million for the year ended December 31, 2022, and total revenue of $12.8 million for the fourth quarter of 2022.
  • Total gross margin was 50.9% in the fourth quarter of 2022 compared to 61.1% in the fourth quarter of 2021.
  • Operating expenses were $27.3 million in the fourth quarter of 2022, compared to $18.9 million in the fourth quarter of 2021.